SYNB 1020

Drug Profile

SYNB 1020

Alternative Names: SYNB-1020

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synlogic
  • Class Probiotics
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hyperammonaemia; Liver cirrhosis
  • Phase I Inborn urea cycle disorders

Most Recent Events

  • 12 Mar 2018 Pharmacodynamics data from a preclinical trial in Hyperammonaemia released by Synlogic
  • 12 Mar 2018 Pharmacokinetics data from a phase I trial in Hyperammonaemia released by Synlogic
  • 28 Feb 2018 Phase-I/II clinical trials in Cirrhosis (In adults, In the elderly) in USA (PO) (NCT03447730)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top